Chemed (NYSE:CHE – Get Free Report) and BrightSpring Health Services (NASDAQ:BTSG – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk. Institutional & Insider Ownership 95.8% of Chemed shares […]
Hanson & Doremus Investment Management lessened its stake in shares of Chemed Co. (NYSE:CHE – Free Report) by 1.1% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 3,262 shares of the company’s stock after selling 37 shares during the period. Hanson & Doremus Investment Management’s holdings in Chemed were worth $1,907,000 at […]
Hanson & Doremus Investment Management cut its holdings in Chemed Co. (NYSE:CHE – Free Report) by 1.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,262 shares of the company’s stock after selling 37 shares during the period. Hanson & Doremus […]
Riverbridge Partners LLC trimmed its holdings in Chemed Co. (NYSE:CHE – Free Report) by 1.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 97,074 shares of the company’s stock after selling 1,196 shares during the period. Riverbridge Partners LLC owned 0.64% […]
AUSTIN, Texas, April 05, 2024 Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced an analysis from the IMvigor011 study that was presented at the European Association of Urology (EAU) Congress 2024 in Paris, France. The analysis evaluates outcomes in muscle-invasive bladder cancer (MIBC) patients who tested serially negative with Signatera™, Natera’s personalized and tumor-informed molecular residual disease (MRD) test.